LAVIPHARM S.A. (CR)LAVIPHARM S.A. (CR)LAVIPHARM S.A. (CR)

LAVIPHARM S.A. (CR)

No trades
See on Supercharts
Market capitalization
‪121.29 M‬EUR
0.044EUR
‪1.87 M‬EUR
‪50.93 M‬EUR
‪69.04 M‬
Beta (1Y)
1.27
Employees (FY)
307
Change (1Y)
+25 +8.87%
Revenue / Employee (1Y)
‪183.10 K‬EUR
Net income / Employee (1Y)
‪7.18 K‬EUR

About LAVIPHARM S.A. (CR)


Headquarters
Paiania
Founded
1911
ISIN
GRS246003008
FIGI
BBG000FRM981
Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. It offers products such as pharmaceuticals, over the counter medicines, and dermacosmetics. The company was founded in 1911 and is headquartered in Paiania, Greece.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of LAVI is 0.734 EUR — it has increased by 0.97% in the past 24 hours. Watch LAVIPHARM S.A. (CR) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ATHEX exchange LAVIPHARM S.A. (CR) stocks are traded under the ticker LAVI.
LAVI stock has fallen by −7.63% compared to the previous week, the month change is a −3.46% fall, over the last year LAVIPHARM S.A. (CR) has showed a 4.26% increase.
LAVI reached its all-time high on Jan 15, 2007 with the price of 6.198 EUR, and its all-time low was 0.050 EUR and was reached on Sep 19, 2016. View more price dynamics on LAVI chart.
See other stocks reaching their highest and lowest prices.
LAVI stock is 2.79% volatile and has beta coefficient of 1.27. Track LAVIPHARM S.A. (CR) stock price on the chart and check out the list of the most volatile stocks — is LAVIPHARM S.A. (CR) there?
Today LAVIPHARM S.A. (CR) has the market capitalization of ‪122.47 M‬, it has decreased by −8.10% over the last week.
Yes, you can track LAVIPHARM S.A. (CR) financials in yearly and quarterly reports right on TradingView.
LAVI net income for the last half-year is ‪7.74 M‬ EUR, while the previous report showed ‪−347.00 K‬ EUR of net income which accounts for ‪2.33 K‬% change. Track more LAVIPHARM S.A. (CR) financial stats to get the full picture.
No, LAVI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 26, 2024, the company has 307.00 employees. See our rating of the largest employees — is LAVIPHARM S.A. (CR) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LAVIPHARM S.A. (CR) EBITDA is ‪6.94 M‬ EUR, and current EBITDA margin is 16.39%. See more stats in LAVIPHARM S.A. (CR) financial statements.
Like other stocks, LAVI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LAVIPHARM S.A. (CR) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LAVIPHARM S.A. (CR) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LAVIPHARM S.A. (CR) stock shows the neutral signal. See more of LAVIPHARM S.A. (CR) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.